What is CD4+CD56+ malignancy and how should it be treated?

CD4+CD56+ malignancy is a rare neoplasm with a typical clinical pattern, an aggressive course and high early relapse rate despite good initial response to chemotherapy. In this review, the impact of different therapeutic approaches on clinical outcome has been studied. We evaluated 91 published case...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimer, P, Rüdiger, T, Kraemer, D, Kunzmann, V, Weissinger, F, Zettl, A, Konrad Müller-Hermelink, H, Wilhelm, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2003
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091947/
https://www.ncbi.nlm.nih.gov/pubmed/13130309
http://dx.doi.org/10.1038/sj.bmt.1704215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091947/
https://www.ncbi.nlm.nih.gov/pubmed/13130309
http://dx.doi.org/10.1038/sj.bmt.1704215

Ejemplares similares